SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Voke® (DEV200) update

3 Jan 2017 07:00

RNS Number : 1264T
Consort Medical PLC
03 January 2017
 

 

Consort Medical plc

 

03 January 2017

 

Voke® (DEV200) update

 

Consort Medical plc ("Consort Medical") (LSE: CSRT) today announces that Nicovations Limited ("Nicovations"), a wholly-owned subsidiary of British American Tobacco plc ("BAT"), has served termination notices for all Supply Agreements with Bespak Europe Limited ("Bespak"), a Consort Medical subsidiary, for Voke®. Termination is effective immediately.

 

· Nicovations has terminated all supply agreements with Bespak for Voke, an MHRA approved nicotine inhaler for harm reduction in smoking

· Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future of the Voke programme

· Voke is one of 16 programmes in Bespak's growing development pipeline and Consort Medical's Board at this time does not believe that the Termination materially impacts their expectations for the Group's underlying trading performance for the current financial year

 

Nicovations has terminated the Supply Agreements on the basis of lack of commercial launch of Voke before 31 December 2016, which is a termination right provided for in the Supply Agreements that Nicovation has chosen to invoke.

 

Voke, one of 16 programmes in Bespak's development pipeline, was designed by Kind Consumer, a developer of innovative, medically-authorised products, for licensing into consumer and pharmaceutical markets. The distribution rights to the product were licensed by Kind Consumer to Nicovations and, in relation to this licence agreement, in 2011 Nicovations also entered into separate Supply Agreements with Bespak. The agreements cover the build, manufacturing and supply of the filled Voke devices and associated valves.

 

Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future supply of the Voke nicotine inhaler which addresses a fast growing multi-billion dollar market.

 

With a robust financial position and a strong development pipeline, the board of directors of Consort Medical at this time does not believe that the termination of the Supply Agreements materially impacts their expectations for Consort Medical Group's underlying trading performance for the current financial year ending 30 April 2017.

 

Jonathan Glenn, Chief Executive Officer of Consort Medical, commented:

 

"Our recent interim financial results highlighted the underlying strength in Bespak and Aesica and the momentum emanating from the growing and diverse pipeline portfolio of significant development programmes. Therefore, while we are naturally disappointed in the loss of the Supply Agreements for Voke to Nicovations, we continue our dialogue with Kind Consumer and with Nicovations on the future of the programme and we remain highly confident in the robustness of the remainder of our business and our prospects for the future".

 

- Ends -

 

 

Enquiries:

 

Consort Medical

Tel: +44 1442 867920

Jonathan Glenn - Chief Executive Officer

FTI Consulting

Tel: +44 20 3727 1000

Ben Atwell / Simon Conway

 

 

Notes:

 

Market Abuse Regulations (MAR)

This announcement contains inside information.

 

About Consort Medical

 

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

 

Our businesses

 

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectable products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

 

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

 

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBTMBTMBIMTTR
Date   Source Headline
1st Nov 20179:35 amRNSDirector/PDMR Shareholding
1st Nov 20179:04 amRNSTotal Voting Rights
16th Oct 20179:42 amRNSBlock listing Interim Review
11th Oct 20172:10 pmRNSDirector/PDMR Shareholding
11th Oct 201711:38 amRNSHolding(s) in Company
2nd Oct 201710:03 amRNSTotal Voting Rights
11th Sep 20175:15 pmRNSDirector/PDMR Shareholding
7th Sep 20171:56 pmRNSDirector/PDMR Shareholding
6th Sep 20174:35 pmRNSResult of AGM
1st Sep 20172:47 pmRNSDirector Declaration
10th Aug 20178:38 amRNSDirector/PDMR Shareholding
1st Aug 20177:00 amRNSTotal Voting Rights
28th Jul 20173:48 pmRNSPosting of Annual Financial Report and AGM Notice
26th Jul 20179:22 amRNSDirector/PDMR Shareholding
20th Jul 20178:07 amRNSAdditional Listing
11th Jul 20178:53 amRNSDirector/PDMR Shareholding
21st Jun 201712:10 pmRNSDirector/PDMR Shareholding
21st Jun 201712:09 pmRNSDirector/PDMR Shareholding
21st Jun 201712:09 pmRNSDirector/PDMR Shareholding
21st Jun 201712:09 pmRNSDirector/PDMR Shareholding
15th Jun 20177:00 amRNSFull year results
5th Jun 201710:09 amRNSDirector Declaration
8th May 20177:00 amRNSNotice of Results
2nd May 201711:10 amRNSTotal Voting Rights
27th Apr 201711:51 amRNSResult of General Meeting
18th Apr 20179:36 amRNSBlock listing Interim Review
3rd Apr 20179:49 amRNSNotice of GM
1st Mar 20179:22 amRNSTotal Voting Rights
30th Jan 201712:44 pmRNSHolding(s) in Company
26th Jan 20172:59 pmRNSHolding(s) in Company
23rd Jan 20177:00 amRNSParticipation in equity raise for Atlas Genetics
3rd Jan 20177:00 amRNSVoke® (DEV200) update
15th Dec 20169:45 amRNSHolding(s) in Company
14th Dec 201610:35 amRNSHolding(s) in Company
14th Dec 20167:00 amRNSDirectorate Change
9th Dec 20163:18 pmRNSDirector/PDMR Shareholding
6th Dec 20167:00 amRNSInterim Results
2nd Dec 20169:25 amRNSHolding(s) in Company
1st Dec 20169:43 amRNSTotal Voting Rights
25th Nov 20167:00 amRNSCFO Appointment
8th Nov 20161:24 pmRNSDirector/PDMR Shareholding
1st Nov 201610:15 amRNSTotal Voting Rights
31st Oct 20163:32 pmRNSDirector/PDMR Shareholding
31st Oct 20161:00 pmRNSNotice of Results
27th Oct 20167:00 amRNSCIMZIA® AutoClicks® prefilled pen launched in UK
14th Oct 201610:02 amRNSBlock listing Interim Review
14th Oct 20167:00 amRNSAnnouncement of master development agreement
11th Oct 201612:03 pmRNSDirector/PDMR Shareholding
3rd Oct 20169:00 amRNSTotal Voting Rights
19th Sep 20169:47 amRNSBespak Technology in UCB PrefilledPen EMA Approval

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.